Please Wait
Applying Filters...
Menu
Xls
2D Structure
Also known as: 1323403-33-3, Cc-220, (s)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione, Iberdomide [usan], Cc220, 8v66f27x44
Molecular Formula
C25H27N3O5
Molecular Weight
449.5  g/mol
InChI Key
IXZOHGPZAQLIBH-NRFANRHFSA-N
FDA UNII
8V66F27X44

Iberdomide is a modulator of the E3 ubiquitin ligase complex containing cereblon (CRL4-CRBN E3 ubiquitin ligase), with immunomodulating and pro-apoptotic activities. Upon administration, iberdomide specifically binds to the cereblon (CRBN) part of the ligase complex, thereby affecting the ubiquitin E3 ligase activity, and targeting certain substrate proteins for ubiquitination. This induces the proteasome-mediated degradation of certain transcription factors, including Ikaros (IKZF1) and Aiolos (IKZF3) which are transcriptional repressors in T-cells. This leads to a reduction of their protein levels, and the modulation of the immune system, including activation of T-lymphocytes. In addition, this leads to a downregulation of other proteins, including interferon regulatory factor 4 (IRF4), which plays a key role in the proliferation of certain cancer cell types. CRBN, the substrate recognition component of the E3 ubiquitin ligase complex, plays a key role in the ubiquitination of certain proteins.
1 2D Structure

2D Structure

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(3S)-3-[7-[[4-(morpholin-4-ylmethyl)phenyl]methoxy]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione
2.1.2 InChI
InChI=1S/C25H27N3O5/c29-23-9-8-21(24(30)26-23)28-15-20-19(25(28)31)2-1-3-22(20)33-16-18-6-4-17(5-7-18)14-27-10-12-32-13-11-27/h1-7,21H,8-16H2,(H,26,29,30)/t21-/m0/s1
2.1.3 InChI Key
IXZOHGPZAQLIBH-NRFANRHFSA-N
2.1.4 Canonical SMILES
C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3OCC4=CC=C(C=C4)CN5CCOCC5
2.1.5 Isomeric SMILES
C1CC(=O)NC(=O)[C@H]1N2CC3=C(C2=O)C=CC=C3OCC4=CC=C(C=C4)CN5CCOCC5
2.2 Other Identifiers
2.2.1 UNII
8V66F27X44
2.3 Synonyms
2.3.1 MeSH Synonyms

1. (3s)-3-(4-((4-((morpholin-4-yl)methyl)phenyl)methoxy)-1-oxo-1,3-dihydro-2h-isoindol-2-yl)piperidine-2,6-dione

2. Cc-220

3. Cc-220 Hydrochloride

4. Cc220

5. Iberdomide Hydrochloride

2.3.2 Depositor-Supplied Synonyms

1. 1323403-33-3

2. Cc-220

3. (s)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione

4. Iberdomide [usan]

5. Cc220

6. 8v66f27x44

7. (3s)-3-[4-({4-[(morpholin-4-yl)methyl]phenyl}methoxy)-1-oxo-1,3-dihydro-2h-isoindol-2-yl]piperidine-2,6-dione

8. (3s)-3-[7-[[4-(morpholin-4-ylmethyl)phenyl]methoxy]-3-oxo-1h-isoindol-2-yl]piperidine-2,6-dione

9. 2,6-piperidinedione, 3-(1,3-dihydro-4-((4-(4-morpholinylmethyl)phenyl)methoxy)-1-oxo-2h-isoindol-2-yl)-, (3s)-

10. (3s)-3-(4-((4-((morpholin-4-yl)methyl)phenyl)methoxy)-1-oxo-1,3-dihydro-2h-isoindol-2-yl)piperidine-2,6-dione

11. 8w7

12. Iberdomide(cc220)

13. Iberdomide [inn]

14. Iberdomide (usan/inn)

15. Iberdomide [who-dd]

16. Cc-220 (compound 6)

17. Iberdomide(cc-220)

18. Gtpl9618

19. Schembl2252414

20. Cc 220;cc-220;iberdomide

21. Chembl3989927

22. Unii-8v66f27x44

23. Bdbm65497

24. Bcp20299

25. Ex-a1425

26. Nsc833899

27. S8760

28. Zinc118417658

29. Compound 6 [pmid: 28425720]

30. Cs-6511

31. Db12101

32. Nsc-833899

33. (s)-3-[4-(4-morpholin-4-yl-methyl-benzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]-piperidine-2,6-dione

34. Ac-32713

35. Hy-101291

36. C72310

37. D11134

38. A903376

39. Q27271066

40. Cc220;(s)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;cc-220

2.4 Create Date
2012-11-30
3 Chemical and Physical Properties
Molecular Weight 449.5 g/mol
Molecular Formula C25H27N3O5
XLogP31.1
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count6
Rotatable Bond Count6
Exact Mass449.19507097 g/mol
Monoisotopic Mass449.19507097 g/mol
Topological Polar Surface Area88.2 Ų
Heavy Atom Count33
Formal Charge0
Complexity732
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Treatment of mature B-cell neoplasms